Clinical trial · Interventional
Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
NCT06907797CI-TRIAL-00112227recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 10, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260910-000001
Summary
Brief summary (as posted)
This study aims to test the Tools for Reducing Inequity in Acute Leukemia (TRIAL) web-based application that is designed to support participants with acute leukemia by providing information and resources about leukemia and clinical trial participation.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Leukemia | Acute Leukemia | ONTOLOGY_EXACT | 0.90 |
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TRIAL Web-Based Application | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- TRIAL Web-Based Application
- description
- Enrolled participants will complete: * Baseline visit and questionnaires * Access to web application over the course of 14 days. * End of study questionnaires * 12 participants will take part in semi-structured interviews with study staff which will be audio recorded.
- interventionNames
- Behavioral: TRIAL Web-Based Application
Primary outcomes (3)
- measure
- Post-Test Completion Rate
- timeFrame
- Day 14 or date of discharge
- description
- Defined as the proportion of completed post-tests compared to the overall total of 75. Retention feasibility is defined as ≥ 70% of post-test completions, or 53 completions.
- measure
- System Usability Scale (SUS) Score
- timeFrame
- Day 14 or date of discharge
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 or older * English speaking * Ability to understand and willingness to sign written informed consent * Clinical suspicion of acute leukemia * Admitted to DFCI-affiliated inpatient unit Exclusion Criteria: * Cognitive impairment rendering the individual unable to participate in beta testing * This will be assessed by focused chart review and consultation with the patients' inpatient care team. * The following populations will be excluded: adults unable to consent, individuals who are not yet adults (infants, children, teenagers \<18 years old), prisoners. * Inability to participate in in-person application testing. * Patients who participated in alpha-testing through protocol 23-404 (Appendix A)
References
Publications (0)
Data not yet available
No reference posted for this study.